anagrelide hydrochloride

DRUG3 trials

Sponsors

Shire

Conditions

Essential ThrombocythaemiaEssential Thrombocythemia (ET)

Phase 2

The Pharmacokinetics of Anagrelide in Elderly and Young Patients With Essential Thrombocythaemia (ET)

CompletedNCT00413634

ShireEssential Thrombocythaemia

Start: 2006-11-13End: 2008-01-22Updated: 2021-06-29

Phase 3

Effect of SPD422 on Platelet Lowering and Safety in Japanese Adults With At Risk Essential Thrombocythaemia

CompletedNCT01214915

ShireEssential Thrombocythemia (ET)

Start: 2010-10-27End: 2012-10-24Updated: 2021-06-09

Unknown Phase

Exploratory Multi-centre Trial In Patients With ET Treated With XAGRID®

CompletedNCT01352585

ShireEssential Thrombocythemia (ET)

Start: 2011-07-19End: 2013-09-19Updated: 2021-07-30

Related Papers

Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating study

Drug Design Development and Therapy2015-05-019 citations